SILO: Silo Pharma, Inc. Stock

by  •  • Comments Off on SILO: Silo Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.94
Enterprise Value ($M) 3.08
Book Value ($M) 6.78
Book Value / Share 1.51
Price / Book 1.17
NCAV ($M) 6.48
NCAV / Share 1.44
Price / NCAV 1.23

Profitability (mra)
Return on Invested Capital (ROIC) -0.56
Return on Assets (ROA) -0.49
Return on Equity (ROE) -0.61

Liquidity (mrq)
Quick Ratio 7.91
Current Ratio 7.91

Balance Sheet (mrq) ($M)
Current Assets 8.26
Assets 8.57
Liabilities 1.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-13 13G Renaissance Technologies Llc
07-26 13G Intracoastal Capital, Llc 4.99 21.82
2024-01-25 13G/A Reda Joseph 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UND
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SE
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER S
2024-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 85,676 197,152 43.46
2025-02-03 238,852 632,117 37.79
2025-01-31 114,241 424,764 26.90
2025-01-30 27,837 143,751 19.36

(click for more detail)

Similar Companies
SCLX – Scilex Holding Company SGMO – Sangamo Therapeutics, Inc.
SHPH – Shuttle Pharmaceuticals Holdings, Inc. SLGL – Sol-Gel Technologies Ltd.
SLRX – Salarius Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io